Annual CFF
-$1.34 M
-$19.52 M-107.39%
31 December 2023
Summary:
Enveric Biosciences annual cash flow from financing activities is currently -$1.34 million, with the most recent change of -$19.52 million (-107.39%) on 31 December 2023. During the last 3 years, it has fallen by -$6.87 million (-124.28%). ENVB annual CFF is now -105.39% below its all-time high of $24.90 million, reached on 31 December 2021.ENVB Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$517.70 K
+$483.30 K+1404.94%
30 September 2024
Summary:
Enveric Biosciences quarterly cash flow from financing activities is currently $517.70 thousand, with the most recent change of +$483.30 thousand (+1404.94%) on 30 September 2024. Over the past year, it has increased by +$622.70 thousand (+593.05%). ENVB quarterly CFF is now -97.92% below its all-time high of $24.88 million, reached on 31 March 2021.ENVB Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$7.02 M
+$622.70 K+9.73%
30 September 2024
Summary:
Enveric Biosciences TTM cash flow from financing activities is currently $7.02 million, with the most recent change of +$622.70 thousand (+9.73%) on 30 September 2024. Over the past year, it has increased by +$8.18 million (+707.06%). ENVB TTM CFF is now -75.55% below its all-time high of $28.73 million, reached on 30 June 2021.ENVB TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ENVB Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -107.4% | +593.0% | +707.1% |
| 3 y3 years | -124.3% | +100.0% | -75.3% |
| 5 y5 years | -149.9% | +100.0% | +215.8% |
ENVB Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -105.4% | at low | -94.5% | +149.2% | -75.3% | +623.0% |
| 5 y | 5 years | -105.4% | at low | -97.9% | +135.3% | -75.5% | +623.0% |
| alltime | all time | -105.4% | +1.6% | -97.9% | +132.6% | -75.5% | +605.6% |
Enveric Biosciences Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $517.70 K(+1404.9%) | $7.02 M(+9.7%) |
| June 2024 | - | $34.40 K(-99.5%) | $6.40 M(+20.4%) |
| Mar 2024 | - | $6.66 M(-3677.8%) | $5.32 M(-495.7%) |
| Dec 2023 | -$1.34 M(-107.4%) | -$186.10 K(+77.2%) | -$1.34 M(+16.1%) |
| Sept 2023 | - | -$105.00 K(-90.0%) | -$1.16 M(-117.1%) |
| June 2023 | - | -$1.05 M(<-9900.0%) | $6.77 M(-22.9%) |
| Mar 2023 | - | $0.00(0.0%) | $8.78 M(-51.7%) |
| Dec 2022 | $18.18 M(-27.0%) | $0.00(-100.0%) | $18.18 M(0.0%) |
| Sept 2022 | - | $7.82 M(+716.7%) | $18.18 M(+75.6%) |
| June 2022 | - | $958.00 K(-89.8%) | $10.36 M(+10.0%) |
| Mar 2022 | - | $9.40 M(>+9900.0%) | $9.42 M(-62.2%) |
| Dec 2021 | $24.90 M(+350.2%) | $0.00(0.0%) | $24.90 M(-12.6%) |
| Sept 2021 | - | $0.00(-100.0%) | $28.50 M(-0.8%) |
| June 2021 | - | $17.90 K(-99.9%) | $28.73 M(+5.5%) |
| Mar 2021 | - | $24.88 M(+591.3%) | $27.24 M(+392.5%) |
| Dec 2020 | $5.53 M(+207.7%) | $3.60 M(+1482.0%) | $5.53 M(+207.6%) |
| Sept 2020 | - | $227.50 K(-115.5%) | $1.80 M(+14.5%) |
| June 2020 | - | -$1.47 M(-146.3%) | $1.57 M(-55.4%) |
| Mar 2020 | - | $3.17 M(-2465.7%) | $3.52 M(+95.9%) |
| Dec 2019 | $1.80 M(-33.3%) | -$134.10 K(<-9900.0%) | $1.80 M(-19.2%) |
| Sept 2019 | - | $0.00(-100.0%) | $2.22 M(-69.2%) |
| June 2019 | - | $483.80 K(-66.6%) | $7.23 M(+26.1%) |
| Mar 2019 | - | $1.45 M(+394.8%) | $5.73 M(+112.8%) |
| Dec 2018 | $2.69 M(-58.0%) | $292.60 K(-94.2%) | $2.69 M(-64.0%) |
| Sept 2018 | - | $5.01 M(-593.3%) | $7.49 M(+214.2%) |
| June 2018 | - | -$1.01 M(-36.2%) | $2.38 M(-31.7%) |
| Mar 2018 | - | -$1.59 M(-131.3%) | $3.49 M(-45.6%) |
| Dec 2017 | $6.41 M(-27.1%) | $5.09 M(-5268.3%) | $6.41 M(+875.6%) |
| Sept 2017 | - | -$98.40 K(-210.7%) | $657.30 K(-87.0%) |
| June 2017 | - | $88.90 K(-93.3%) | $5.05 M(-48.9%) |
| Mar 2017 | - | $1.34 M(-299.5%) | $9.89 M(+12.4%) |
| Dec 2016 | $8.80 M(+41.1%) | -$670.00 K(-115.6%) | $8.80 M(-7.1%) |
| Sept 2016 | - | $4.30 M(-12.9%) | $9.47 M(+74.6%) |
| June 2016 | - | $4.93 M(+1941.4%) | $5.42 M(-4.1%) |
| Mar 2016 | - | $241.50 K(-3.4%) | $5.65 M(+4.5%) |
| Dec 2015 | $6.24 M(>+9900.0%) | - | - |
| Sept 2015 | - | $250.00 K(-95.2%) | $5.41 M(+4.8%) |
| June 2015 | - | $5.16 M(>+9900.0%) | $5.16 M(<-9900.0%) |
| Mar 2015 | - | $0.00(0.0%) | -$2000.00(-104.2%) |
| Dec 2014 | $48.00 K(+134.1%) | $0.00(0.0%) | $48.00 K(0.0%) |
| Sept 2014 | - | $0.00(-100.0%) | $48.00 K(-6.8%) |
| June 2014 | - | -$2000.00(-104.0%) | $51.50 K(-12.0%) |
| Mar 2014 | - | $50.00 K(>+9900.0%) | $58.50 K(+185.4%) |
| Dec 2013 | $20.50 K(+156.3%) | $0.00(-100.0%) | $20.50 K(-12.8%) |
| Sept 2013 | - | $3500.00(-30.0%) | $23.50 K(-6.0%) |
| June 2013 | - | $5000.00(-58.3%) | $25.00 K(+25.0%) |
| Mar 2013 | - | $12.00 K(+300.0%) | $20.00 K(+150.0%) |
| Dec 2012 | $8000.00(-83.2%) | $3000.00(-40.0%) | $8000.00(+1.3%) |
| Sept 2012 | - | $5000.00(>+9900.0%) | $7900.00(-65.5%) |
| June 2012 | - | $0.00(0.0%) | $22.90 K(-22.4%) |
| Mar 2012 | - | $0.00(-100.0%) | $29.50 K(-37.9%) |
| Dec 2011 | $47.50 K(+18.8%) | $2900.00(-85.5%) | $47.50 K(+6.5%) |
| Sept 2011 | - | $20.00 K(+203.0%) | $44.60 K(-31.0%) |
| June 2011 | - | $6600.00(-63.3%) | $64.60 K(+153.3%) |
| Mar 2011 | - | $18.00 K(>+9900.0%) | $25.50 K(-36.3%) |
| Dec 2010 | $40.00 K | $0.00(-100.0%) | $40.00 K(+1042.9%) |
| Sept 2010 | - | $40.00 K(-223.1%) | $3500.00(>+9900.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2010 | - | -$32.50 K(-200.0%) | $0.00(-100.0%) |
| Mar 2010 | - | $32.50 K(-189.0%) | $32.50 K(>+9900.0%) |
| Dec 2009 | $0.00(-100.0%) | -$36.50 K(-200.0%) | $0.00(-100.0%) |
| Sept 2009 | - | $36.50 K(>+9900.0%) | $46.20 K(+376.3%) |
| June 2009 | - | $0.00(0.0%) | $9700.00(-100.7%) |
| Mar 2009 | - | $0.00(-100.0%) | -$1.36 M(-0.7%) |
| Dec 2008 | -$1.36 M(-465.7%) | $9700.00(>+9900.0%) | -$1.36 M(-1.7%) |
| Sept 2008 | - | $0.00(-100.0%) | -$1.39 M(+22.0%) |
| June 2008 | - | -$1.36 M(>+9900.0%) | -$1.14 M(-405.1%) |
| Mar 2008 | - | -$9700.00(-33.1%) | $373.30 K(0.0%) |
| Dec 2007 | $373.30 K(<-9900.0%) | -$14.50 K(-105.8%) | $373.30 K(0.0%) |
| Sept 2007 | - | $250.10 K(+69.7%) | $373.30 K(+228.9%) |
| June 2007 | - | $147.40 K(-1619.6%) | $113.50 K(<-9900.0%) |
| Mar 2007 | - | -$9700.00(-33.1%) | -$100.00(-87.5%) |
| Dec 2006 | -$800.00(-98.6%) | -$14.50 K(+49.5%) | -$800.00(-93.4%) |
| Sept 2006 | - | -$9700.00(-128.7%) | -$12.20 K(-63.3%) |
| June 2006 | - | $33.80 K(-425.0%) | -$33.20 K(-16.8%) |
| Mar 2006 | - | -$10.40 K(-59.8%) | -$39.90 K(-28.4%) |
| Dec 2005 | -$55.80 K(+32.9%) | -$25.90 K(-15.6%) | -$55.70 K(-18.8%) |
| Sept 2005 | - | -$30.70 K(-213.3%) | -$68.60 K(+363.5%) |
| June 2005 | - | $27.10 K(-203.4%) | -$14.80 K(-73.2%) |
| Mar 2005 | - | -$26.20 K(-32.5%) | -$55.20 K(+31.4%) |
| Dec 2004 | -$42.00 K(-836.8%) | -$38.80 K(-268.0%) | -$42.00 K(-1780.0%) |
| Sept 2004 | - | $23.10 K(-273.7%) | $2500.00(-103.3%) |
| June 2004 | - | -$13.30 K(+2.3%) | -$75.60 K(+935.6%) |
| Mar 2004 | - | -$13.00 K(-328.1%) | -$7300.00(-228.1%) |
| Dec 2003 | $5700.00(>+9900.0%) | $5700.00(-110.4%) | $5700.00(>+9900.0%) |
| Sept 2003 | - | -$55.00 K(-200.0%) | $0.00(-100.0%) |
| June 2003 | - | $55.00 K(>+9900.0%) | $55.00 K(>+9900.0%) |
| Mar 2003 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2002 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Sept 2002 | - | $0.00(0.0%) | $0.00(0.0%) |
| June 2002 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Mar 2002 | - | $0.00(0.0%) | -$224.20 K(0.0%) |
| Dec 2001 | -$224.20 K(-149.1%) | $0.00(0.0%) | -$224.20 K(+10.4%) |
| Sept 2001 | - | $0.00(-100.0%) | -$203.10 K(+6.2%) |
| June 2001 | - | -$224.20 K(<-9900.0%) | -$191.20 K(-679.4%) |
| Mar 2001 | - | $0.00(-100.0%) | $33.00 K(-92.8%) |
| Dec 2000 | $456.40 K(-68.4%) | $21.10 K(+77.3%) | $456.50 K(+4.8%) |
| Sept 2000 | - | $11.90 K(>+9900.0%) | $435.40 K(+2.8%) |
| June 2000 | - | $0.00(-100.0%) | $423.50 K(0.0%) |
| Mar 2000 | - | $423.50 K(-2069.8%) | $423.50 K(-85.8%) |
| Dec 1999 | $1.45 M(-51.4%) | - | - |
| Dec 1998 | $2.98 M(-8.6%) | -$21.50 K(-121.5%) | $2.98 M(-28.4%) |
| Sept 1998 | - | $100.00 K(-96.2%) | $4.16 M(0.0%) |
| June 1998 | - | $2.60 M(+766.7%) | $4.16 M(+166.8%) |
| Mar 1998 | - | $300.00 K(-74.1%) | $1.56 M(-52.2%) |
| Dec 1997 | $3.26 M(-28.3%) | $1.16 M(+1058.5%) | $3.26 M(+39.0%) |
| Sept 1997 | - | $100.00 K(>+9900.0%) | $2.34 M(-33.9%) |
| June 1997 | - | $0.00(-100.0%) | $3.54 M(-46.7%) |
| Mar 1997 | - | $2.00 M(+716.7%) | $6.64 M(+46.2%) |
| Dec 1996 | $4.54 M(-15.8%) | $244.90 K(-81.2%) | $4.54 M(+5.7%) |
| Sept 1996 | - | $1.30 M(-58.1%) | $4.30 M(+43.3%) |
| June 1996 | - | $3.10 M(-3200.0%) | $3.00 M(-3100.0%) |
| Mar 1996 | - | -$100.00 K | -$100.00 K |
| Dec 1995 | $5.40 M(+671.4%) | - | - |
| Dec 1994 | $700.00 K(-79.4%) | - | - |
| Aug 1994 | $3.40 M | - | - |
FAQ
- What is Enveric Biosciences annual cash flow from financing activities?
- What is the all time high annual CFF for Enveric Biosciences?
- What is Enveric Biosciences annual CFF year-on-year change?
- What is Enveric Biosciences quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Enveric Biosciences?
- What is Enveric Biosciences quarterly CFF year-on-year change?
- What is Enveric Biosciences TTM cash flow from financing activities?
- What is the all time high TTM CFF for Enveric Biosciences?
- What is Enveric Biosciences TTM CFF year-on-year change?
What is Enveric Biosciences annual cash flow from financing activities?
The current annual CFF of ENVB is -$1.34 M
What is the all time high annual CFF for Enveric Biosciences?
Enveric Biosciences all-time high annual cash flow from financing activities is $24.90 M
What is Enveric Biosciences annual CFF year-on-year change?
Over the past year, ENVB annual cash flow from financing activities has changed by -$19.52 M (-107.39%)
What is Enveric Biosciences quarterly cash flow from financing activities?
The current quarterly CFF of ENVB is $517.70 K
What is the all time high quarterly CFF for Enveric Biosciences?
Enveric Biosciences all-time high quarterly cash flow from financing activities is $24.88 M
What is Enveric Biosciences quarterly CFF year-on-year change?
Over the past year, ENVB quarterly cash flow from financing activities has changed by +$622.70 K (+593.05%)
What is Enveric Biosciences TTM cash flow from financing activities?
The current TTM CFF of ENVB is $7.02 M
What is the all time high TTM CFF for Enveric Biosciences?
Enveric Biosciences all-time high TTM cash flow from financing activities is $28.73 M
What is Enveric Biosciences TTM CFF year-on-year change?
Over the past year, ENVB TTM cash flow from financing activities has changed by +$8.18 M (+707.06%)